Using the patient’s own immune system to combat cancer

For over a century, oncologists have relied on chemotherapy to treat cancer. These drugs target rapidly dividing cells—such as cancer cells and, unfortunately, healthy hair follicles—disrupting their replication process to destroy them. If a high enough dose or the right combination of drugs is administered, it is theoretically possible to eradicate all tumor cells. In reality, however, chemotherapy usually eliminates only a majority of them. Administering too much medication leads to severe systemic toxicity and unacceptable side effects, turning chemotherapy treatment into a delicate balancing act. Unfortunately, resistance complicates this approach. Cells are naturally programmed to expel toxins, meaning that over time, tumor cells adapt and build a resistance to the chemotherapy, often leading to a patient relapse. While subsequent treatments may offer temporary relief, they typically yield diminishing returns. Eventually, the cancer progresses, and the patient succumbs to the disease. This heartbreaking pattern is identical in veterinary medicine; traditional chemotherapy has a definitive ceiling. The Limits of Standard Care In canine osteosarcoma, the traditional standard of care is limb amputation followed by four to six doses of carboplatin over a three-to-four-month period. The median survival time with this approach is only about 6 – 11 months. Without amputation, survival drops to approximately three months, and without chemotherapy, it is less than a month. Regrettably, these statistics have remained virtually unchanged for 30 years. A New Frontier: Immunotherapy In 2016, a small biotech company named Elias Animal Health developed a completely different approach, leveraging the body’s own immune system to fight the disease. The immune system can be trained to recognize foreign threats like bacteria and viruses when exposed to inactivated versions of these threats. Once the body identifies the target, it deploys an army of specialized immune cells to destroy the invaders—the foundational principle of vaccination. The Elias protocol begins by harvesting tumor cells from a dog's amputated limb. These cells are sent to a laboratory where they are kept alive but disabled, then injected back into the patient to stimulate an immune response. However, because cancer is highly adept at evading immune detection, this step alone has a limited effect. To overcome this, the protocol introduces a second phase. Once the patient's immune system has had time to recognize the cancer and manufacture an army of immune cells, these cells called T- cells are harvested from the blood through a process called apheresis. (This is similar to dialysis for kidney disease, except that instead of filtering out toxins, specific immune cells are isolated). These harvested T-cells are sent back to the laboratory to be "supercharged" and expanded before being infused back into the patient. Promising Results and Ongoing Trials In a multicenter clinical trial evaluating dogs treated with either traditional carboplatin or Elias Cancer Immunotherapy (ECI), the results were highly encouraging. Dogs receiving ECI showed outcomes comparable to traditional treatments but with far fewer side effects. Interestingly, some of the dogs that did respond well to the vaccine went on to live for several more years – far longer than would be expected with carboplatin alone. In a subsequent, ongoing prospective clinical trial, dogs were given a single introductory dose of chemotherapy before proceeding with the Elias protocol. One single dose seemed to be enough to dramatically increase the response rate by “softening up” the cancer cells making them more visible and vulnerable to the immune system. On average, around 25% of dogs treated with carboplatin live beyond a year. For the Elias population it was 83%. Many of these dogs are still alive today. (May, 2026) This study is just one example of many clinical trials currently underway across the country to pioneer new cancer therapies. Pets enrolled in these trials gain access to cutting-edge medicine, and the data gathered directly contributes to developing treatments that will save thousands of animals in the future. Elias is currently enrolling patients for a new osteosarcoma trial at the University of Missouri.